Esperion Investor Class Wins Cert. In Cholesterol Drug Row
A Michigan federal judge on Sunday certified a class of investors accusing Esperion Therapeutics Inc. of falsely stating that the U.S. Food and Drug Administration wouldn't be requiring a time-consuming study...To view the full article, register now.
Already a subscriber? Click here to view full article